Drug intelligence / Profile preview

RhD positive red blood cells

Development stage
Unknown
Lead developer
American Red Cross
Modality
Cell Therapies
Administration
Intravenous
01

Overview

RhD positive red blood cells are a human blood component characterized by the presence of the Rhesus D (RhD) antigen on the erythrocyte surface. They are primarily administered via transfusion to increase a patient's oxygen-carrying capacity in the setting of acute blood loss (hemorrhage) or chronic anemia. In clinical practice, these cells are typically prepared as packed red blood cells (PRBCs) after most plasma has been removed. Because the RhD antigen is highly immunogenic, RhD positive blood is typically reserved for RhD positive recipients. Exposure of RhD negative individuals—particularly females of childbearing potential—to RhD positive cells can lead to RhD allo-immunization, resulting in hemolytic transfusion reactions or hemolytic disease of the fetus and newborn (HDFN) in future pregnancies. Management of accidental exposure often involves the administration of high-dose anti-D immunoglobulin to clear the RhD positive cells from circulation.

Other names
RhD positive RBCsRhD positive packed red blood cellsRh-positive erythrocytesRhD+ PRBCsRh-positive bloodRhesus D positive red blood cells

Beyond the preview

Go deeper on RhD positive red blood cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RhD positive red blood cells.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call